Open and Flexible Platform

BBIOMIC® is an unique PEA-based multiplexed platform to investigate and validate cosmetic ingredients for specific claims.

Proximity
Extension
Assay

PEA is a novel multiplex technology developed to measure secreted proteins in serum, plasma and culture supernatants. The technology has been proven to possess exceptional readout specificity and sensitivity, enabling high multiplex assays with coverage across a broad dynamic range.

BBIOMIC® explores the levels of 20 validated proteins of cosmetic interest secreted by dermal primary cells in a single well.

BBIOMIC® is designed to study major pathways including UVB, UVA, TLR4, TNFα/IL1β, PKC and HIF pathways in dermal cells (Keratinocytes, Fibroblast, Melanocytes, Dermal Papilla Cells and Dermal Microvascular Endothelial Cells).

BBIOMIC®v is useful to validate cosmetic ingredients and to screen novel activities in primary cells.

BBIOMIC® is an open and flexible platform, customer can design tailor made experiments for many specific claims.

A. In PEA, matched pairs of oligonucleotide-labeled antibodies will bind to their target antigens in a pairwise manner.

B. Upon antibody binding, the matched oligonucleotides are brought into proximity and with the use of a DNA polymerase, a PCR target sequence is created, amplified, detected, and quantified.

C. This downstream process is carried out by microfluidic qPCR.

Assays in human primary
immortalized skin cells.

  • BBIOMIC platform validated in human primary cells.
  • Unique PEA-platform designed for cosmetic research.
  • Superior sensitivity to other immuno-based assays.
  • Flexible platform, customer can choose specific treatment and cell type.
  • 20 selected proteins for a wide number of specific claims.